BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260416T190000
DTEND;TZID=Africa/Nairobi:20260416T203000
DTSTAMP:20260527T024009
CREATED:20260526T192507Z
LAST-MODIFIED:20260526T193940Z
UID:41705-1776366000-1776371400@kesho-kenya.org
SUMMARY:Bridging Surgery and Oncology in Head & Neck Cancer
DESCRIPTION:Moderator: Dr. Ahmed Komen\nSpeakers: Dr. Anthony Kenyanya\, Dr. Anthony Ndiritu\nDate: 16 April 2026\n\nThis session explored the management of head and neck cancer with particular attention to how surgical decisions and oncology pathways must align from the outset. Through oral cavity cancer as a key focus\, the session examined resectability\, margins\, nodal management\, reconstruction\, adjuvant therapy and functional outcomes. \nA central theme was that treatment planning must go beyond tumour removal. Dr. Anthony Kenyanya highlighted the importance of staging\, imaging\, pathology\, dental and nutritional assessment\, surgical access\, margin planning and neck node evaluation. In oral cavity cancers\, surgical success depends not only on clear oncologic resection\, but also on the ability to reconstruct defects and preserve speech\, swallowing\, appearance and quality of life. \nThe discussion also emphasised the challenge of late presentation and complex anatomy. Selective neck dissection\, sentinel node considerations\, access procedures such as mandibulotomy\, and the reconstructive ladder were framed as tools for balancing disease control with morbidity. The role of the pathologist and margin assessment was highlighted as central to determining risk and guiding further treatment. \nDr. Anthony Ndiritu built on this by outlining how radiotherapy and chemoradiation fit into early\, locally advanced\, post-operative\, recurrent and metastatic diseases. Early-stage disease may often be treated with a single modality\, while locally advanced disease requires careful integration of surgery\, radiotherapy and chemotherapy. \nPositive margins and extranodal extension were discussed as major indications for post-operative chemoradiation\, with timely initiation of treatment after surgery being important. The session also addressed treatment technique\, patient fitness\, nutrition\, supportive care and the need to tailor recommendations to the services and expertise available. \nAcross the session\, a consistent message emerged: head and neck cancer care is as much about function\, coordination and follow-through as it is about disease control. \nKey Takeaways\n\nHead and neck cancer decisions must integrate tumour stage\, resectability\, patient fitness and functional outcomes.\nMargin planning\, pathology reporting and neck node assessment directly shape adjuvant treatment decisions.\nSurgery requires strong reconstruction and rehabilitation planning to preserve speech\, swallowing and appearance.\nLocally advanced disease often needs combined-modality treatment through an MDT approach.\nPositive margins and extranodal extension are key triggers for post-operative chemoradiation.\nSupportive care\, nutrition and patient navigation are essential to treatment completion.
URL:https://kesho-kenya.org/event/bridging-surgery-and-oncology-in-head-neck-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Bridging-Surgery-and-Oncology-in-Head-Neck-Cancer-e1779824360609.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260430T190000
DTEND;TZID=Africa/Nairobi:20260430T203000
DTSTAMP:20260527T024009
CREATED:20260526T192028Z
LAST-MODIFIED:20260526T194041Z
UID:41701-1777575600-1777581000@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Testicular Cancer
DESCRIPTION:Moderator: Dr. Muigai Mararo\nSpeakers: Dr. Dedan Opondo\, Dr. Joseph Abuodha\, Dr. George Ogweno\nDate: 30 April 2026\n\nThis session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis\, primary management\, advanced disease\, relapse and fertility preservation. \nA central theme was that testicular cancer is highly curable when investigated and managed promptly\, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition\, scrotal ultrasound\, serum tumour markers\, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed\, particularly because some germ cell tumours can progress rapidly. \nStaging was presented as a practical foundation for management. Tumour markers such as AFP\, beta-HCG and LDH\, together with nodal imaging and histology\, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance\, chemotherapy\, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men. \nDr. Joseph Abuodha reviewed advanced and relapsed disease\, emphasising that treatment remains strongly anchored in surgery\, cisplatin-based chemotherapy\, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages\, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy. \nDr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling\, sperm banking where possible before treatment\, and stronger collaboration between oncology\, urology\, fertility specialists\, laboratories and counsellors. The discussion also reflected Kenya’s service realities\, including limited fertility centres and the need for clearer pathways\, consent and long-term storage planning. \nAcross the session\, a consistent message emerged: testicular cancer care must protect both survival and survivorship. \nKey Takeaways\n\nEarly recognition\, tumour markers\, imaging and radical inguinal orchiectomy are central to initial management.\nRisk stratification using histology\, TNM stage and post-operative markers guides treatment intensity.\nSeminoma and non-seminoma pathways differ and should not be managed interchangeably.\nCisplatin-based chemotherapy remains central in advanced and relapsed disease.\nSurveillance is appropriate only when reliable follow-up is possible.\nFertility counselling and sperm preservation should be discussed as early as possible.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-testicular-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Multidisciplinary-Management-of-Testicular-Cancer.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260507T190000
DTEND;TZID=Africa/Nairobi:20260507T203000
DTSTAMP:20260527T024009
CREATED:20260525T193909Z
LAST-MODIFIED:20260525T210319Z
UID:41667-1778180400-1778185800@kesho-kenya.org
SUMMARY:From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research
DESCRIPTION:Moderator: Rebecca Mwakichako\nDate: 7th May 2026\nSpeakers: Dr. Thomas Chatzikonstantinou\, Ms. Anne Korir \nThis session examined how routine clinical data can be transformed into meaningful research evidence\, with a focus on real-world data\, clinical registries and everyday documentation as a foundation for local oncology research. \nA central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns\, long-term outcomes\, low-prevalence biomarkers\, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions\, clear endpoints and attention to data quality. \nMs. Anne Korir grounded the discussion in the Kenyan cancer registry experience\, highlighting how paper files\, unstructured notes\, missing staging information\, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization\, digitization\, regular data cleaning and ethical governance. \nAcross the session\, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured\, complete and designed with future learning in mind. \n  Key Takeaways \n\nReal-world data complements clinical trials by showing how care is delivered in routine practice.\nRoutine clinical notes can generate locally relevant oncology research questions.\nStandardized documentation is essential for usable research and registry data.\nCancer registries remain critical for surveillance\, policy and outcome tracking.\nCollaboration between clinicians\, registries and research institutions can strengthen local evidence generation.\n\n  \n 
URL:https://kesho-kenya.org/event/from-data-to-discovery-leveraging-registries-and-clinical-insights-to-advance-research/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/From-Data-to-Discovery.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260514T190000
DTEND;TZID=Africa/Nairobi:20260514T203000
DTSTAMP:20260527T024009
CREATED:20260525T203403Z
LAST-MODIFIED:20260525T210044Z
UID:41670-1778785200-1778790600@kesho-kenya.org
SUMMARY:Melanoma Care in Practice: Integrating Dermatology\, Surgery & Oncology
DESCRIPTION:Moderator: Dr Stephen Chege\nDate: 14th May 2026\nSPEAKERS: Dr. Hannah Wanyika\, Dr. Esther Gathura\, Dr. Angela McLigeyo \nThis session examined melanoma care across the clinical pathway\, from recognition of suspicious skin lesions to biopsy\, excision\, reconstruction\, staging and systemic treatment. \nA central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy\, including new or changing pigmented lesions\, non-healing ulcers\, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign\, while emphasizing that changing lesions on the palms\, soles\, nails and scalp should not be dismissed. \nDr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care\, particularly the realities of acral melanoma\, which is common in African populations and often presents late. She emphasized the role of mapping biopsies\, Breslow thickness\, ulceration\, nodal assessment and multidisciplinary planning in balancing oncologic safety with function\, especially for weight-bearing areas of the foot. \nDr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma\, including immune checkpoint inhibitors\, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally\, the session also acknowledged access\, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region. \nAcross the session\, a consistent message emerged: optimal melanoma care depends on early recognition\, accurate biopsy\, careful staging\, function-preserving surgery and realistic access to effective systemic therapy. \nKey Takeaways \n\nChanging pigmented lesions\, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.\nThe ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.\nAcral melanoma presents distinct diagnostic and surgical challenges in African settings.\nSurgical management must balance clear margins\, staging and functional reconstruction.\nImmunotherapy and targeted treatment have changed advanced melanoma care\, but access and local evidence remain key challenges.
URL:https://kesho-kenya.org/event/melanoma-care-in-practice-integrating-dermatology-surgery-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Melanoma-Care.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260521T190000
DTEND;TZID=Africa/Nairobi:20260521T203000
DTSTAMP:20260527T024009
CREATED:20260525T210458Z
LAST-MODIFIED:20260526T194356Z
UID:41677-1779390000-1779395400@kesho-kenya.org
SUMMARY:Bladder Cancer Care
DESCRIPTION:SPEAKERS: Dr. Patrick Mbuthia\, Dr. Helena Musau\, Dr Mohammed Ezzi\nDate: 21st May 2026\nModerator: Dr. Sitna Mwanzi \nThis session examined bladder cancer through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis\, staging and treatment\, particularly for non-muscle invasive disease. The importance of complete resection\, adequate detrusor muscle in the specimen\, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions. \nDr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation\, especially through tri-modality therapy combining maximal TURBT\, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection\, surveillance\, salvage options\, palliative radiotherapy for symptoms\, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life. \nDr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive\, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy\, BCG\, cisplatin eligibility\, immunotherapy\, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents\, while noting that cost and availability continue to shape real-world treatment in Kenya. \nAcross the session\, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis\, high-quality TURBT\, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality. \nKey Takeaways \n\nBladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.\nHigh-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.\nTrimodality therapy offers bladder preservation for carefully selected patients.\nSystemic therapy is rapidly evolving with immunotherapy\, maintenance approaches and antibody-drug conjugates.\nLocal data are needed to address African patterns of disease\, including schistosomiasis-associated squamous cell carcinoma.\n\n 
URL:https://kesho-kenya.org/event/bladder-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Bladder-Cancer-Care-e1779824625799.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260528T190000
DTEND;TZID=Africa/Nairobi:20260528T203000
DTSTAMP:20260527T024009
CREATED:20260525T190142Z
LAST-MODIFIED:20260526T114254Z
UID:41658-1779994800-1780000200@kesho-kenya.org
SUMMARY:Advancing Care Through Multidisciplinary Collaboration
DESCRIPTION:The Brain Tumour JourneyAdvancing Care Through Multidisciplinary Collaboration \nDate: 28th May 2026Time: 7 PM – 8:30 PM EATwww.kesho-kenya.org \nSpeakers & Topics\nDr. Michael MagohaConsultant Neurological Surgeon & Lecturer\, University of Nairobi\, Co-Founder Brain Tumor Association of KenyaThe Beginning of the Brain Tumor Journey – A Neurosurgeon’s Perspective \nDr. Sarah MumaPaediatric Haemato-Oncologist\, Kenyatta National HospitalMultidisciplinary Management of Brain Tumors: Optimizing Outcomes Through Collaborative Care \nParmenas Minda OkwemaSenior Lecturer\, Department of Human Pathology\, University of Nairobi\, Chairman and Founder\, Brain Tumor Association of KenyaUnderstanding Brain Tumour Diagnosis: Pathology Principles and Diagnostic Challenges \nRN Celine KilanyaPaediatric Oncology Nurse\, Kenyatta National HospitalHolistic and Supportive Care in Brain Tumour Management: The Oncology Nurse’s Role in Patient Navigation \nMr. David L. Oluoch-Olunya (Moderator)Consultant Neurological Surgeon\, The Nairobi Hospital & Senior Lecturer\, Aga Khan University Hospital \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-26-at-8.18.55-AM.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260527T024009
CREATED:20260407T183641Z
LAST-MODIFIED:20260519T095620Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
END:VEVENT
END:VCALENDAR